Search Results for 'Pfs-Clinical'

Pfs-Clinical published presentations and documents on DocSlides.

Median PFS: 2.6 months (95% CI, 1.7-3.5)

Median PFS: 2.6 months (95% CI, 1.7-3.5)

by ceila

Median PFS: 1.4 months (95% CI, 1.2-1.6) . Median ...

Pay for Success: Innovative Financing to Improve Child Outcomes

Pay for Success: Innovative Financing to Improve Child Outcomes

by dominic513

Jennifer Tschantz; Early Childhood Research to Pra...

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Ref

by willow

Meletios Dimopoulos,. 1. Hang Quach,. 2. Maria-V...

YIR On Demand Lung Benjamin Levy, MD

YIR On Demand Lung Benjamin Levy, MD

by jovita

Assistant Professor. Johns Hopkins School of Medic...

Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival

Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival

by naomi

David Morgan (King’s College, London / Consultan...

Considerations for Optimizing Transplant in Multiple Myeloma Patient Management

Considerations for Optimizing Transplant in Multiple Myeloma Patient Management

by TravelingSoulmate

PARAMESWARAN HARI MD. MEDICAL COLLEGE OF WISCONSIN...

ESMO 2021 (Virtual) Congress Report

ESMO 2021 (Virtual) Congress Report

by SnuggleBug

Lung and gastrointestinal cancers. Slide numbers. ...

Update on Diagnosis and Treatments

Update on Diagnosis and Treatments

by joanne

of Multiple Myeloma. Kenneth C. Anderson, M.D.. J...

2022 Spring Oncology Conference

2022 Spring Oncology Conference

by byrne

Evolving Treatment Strategies. for CLL/SLL and MCL...

by wang

pfs-full-vlSchema Taxo Fullwith capitalpfs-fullPre...

Nouveautés dans le CBNPC métastatique

Nouveautés dans le CBNPC métastatique

by vizettan

Celine Mascaux, MD, . PhD. Multidisciplinary . Onc...

Game Plan Trends in ovarian cancer

Game Plan Trends in ovarian cancer

by alexa-scheidler

Diagnostic work-up. Treatment. The most commonly ...

Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

Jointly provided by & This activity is supported by educations grants from Novartis Pharmaceuticals Corporation, Pfizer, and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

by olivia-moreira

Jointly provided by ...

Managing Advanced Renal Cell

Managing Advanced Renal Cell

by debby-jeon

Carcinoma: Balancing . Efficacy with Quality of L...

BELLE-3: A Phase III Study of

BELLE-3: A Phase III Study of

by faustina-dinatale

Buparlisib. and . Fulvestrant. in Postmenopausa...

Btk inhibition in Mantle cell Lymphoma & CLL

Btk inhibition in Mantle cell Lymphoma & CLL

by test

Simon Rule. Professor of Clinical . Haematology. ...

Interpretation of the Great Plains Polygonal Fault

Interpretation of the Great Plains Polygonal Fault

by luanne-stotts

Andy St-Onge, Calgary geophysicist@shaw.ca. (i) S...

Her-2 negative MBC

Her-2 negative MBC

by conchita-marotz

10/25/2016. Objectives. General principles. Endoc...

Applying “Pay for Success” Social Impact Finance to Ear

Applying “Pay for Success” Social Impact Finance to Ear

by luanne-stotts

Janis Dubno, Voices for Utah Children. Andrea Phi...

Blinded Sample Size Re-estimation in a Phase III Study Inve

Blinded Sample Size Re-estimation in a Phase III Study Inve

by luanne-stotts

David Morgan (King’s College, London / Consulta...

by danika-pritchard

Director of Solutions Architecture and Field Enab...

Partnerships for Success

Partnerships for Success

by test

Creating Positive School Experiences And Develop...

Beyond Secret Handshakes:

Beyond Secret Handshakes:

by pasty-toler

Affiliation-Hiding Authenticated Key Exchange. Fr...

2014 Oklahoma Business Summit

2014 Oklahoma Business Summit

by marina-yarberry

Sarah Roberts, Inasmuch Foundation, Program Offic...

Analysis of Sustained MRD-Negativity and Progression-Free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma Additional Data From Planned Interim Analysis of the GMMG-CONCEPT Trial

Analysis of Sustained MRD-Negativity and Progression-Free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma Additional Data From Planned Interim Analysis of the GMMG-CONCEPT Trial

by ayaan

Progression-Free Survival of Isa-. KRd. in High-R...

Symptomatic control of functioning pancreatic NET

Symptomatic control of functioning pancreatic NET

by titan

Dr.. . Wouter. T. Zandee, MD, PhD. University Me...

Physician Schedule Proposed Freestanding Radiation Oncology Centers

Physician Schedule Proposed Freestanding Radiation Oncology Centers

by dennis955

Association of Freestanding Radiation Oncology Cen...

INTRODUCTION RESULTS

INTRODUCTION RESULTS

by arjun383

Mason Alford, MSc. a. , . Candace J. Grisham, MS. ...

Please note: The views expressed within this presentation are the personal opinion of the author.

Please note: The views expressed within this presentation are the personal opinion of the author.

by callen

NTRK. and SARCOMA CONNECT groups.. This content i...

Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors i

Learning Objectives Summarize the latest evidence on poly ADP ribose polymerase (PARP) inhibitors i

by zen

knowledge. ). Incorporate evidence-based research ...

Mauricio Lema Medina – Clínica de Oncología Astorga / Clínica SOMA, Medellín

Mauricio Lema Medina – Clínica de Oncología Astorga / Clínica SOMA, Medellín

by delcy

Trastuzumab-emtansine. : A . very. . nice. . poi...

GIULIANA D’AURIA UOC Oncologia ASL Roma 2

GIULIANA D’AURIA UOC Oncologia ASL Roma 2

by hadley

Osp. . Pertini-S.Eugenio-CTO. Therapeutic. . app...

Module 9: HER2-Positive and Triple-Negative BC

Module 9: HER2-Positive and Triple-Negative BC

by unita

Percent with Patients. Number of Patients (Median)...

Treatment escalation in patients with early stage Hodgkin lymphoma and a positive PET scan after in

Treatment escalation in patients with early stage Hodgkin lymphoma and a positive PET scan after in

by fanny

. A subsidiary analysis of the UK NCRI RAPID study...

ECHELON-1: OS Analysis of First-line Brentuximab Vedotin + AVD vs ABVD in Advanced Classical Hodgki

ECHELON-1: OS Analysis of First-line Brentuximab Vedotin + AVD vs ABVD in Advanced Classical Hodgki

by winnie

Supported by educational grants from AbbVie, Astra...

Meeting summary ASCO GU 2020,

Meeting summary ASCO GU 2020,

by patricia

San Francisco. , USA. Assoc. . Prof. . Shilpa Gupt...

Nivolumab + Ipilimumab

Nivolumab + Ipilimumab

by willow

vs . Platinum-Doublet Chemotherapy . as First-line...

meeting summary Autumn 2021 MEETINGS in Multiple Myeloma

meeting summary Autumn 2021 MEETINGS in Multiple Myeloma

by cadie

IMW | SOHO | SOHO Italy. Dr.. Claudio . Cerchione...

1171MO – PACIFIC-R Real-World Study:

1171MO – PACIFIC-R Real-World Study:

by riley

Treatment Duration and Interim Analysis of Progres...

Exploring the Power of Radioimmunobiology

Exploring the Power of Radioimmunobiology

by jaena

. via switching the . Radionuclides, Ligands and I...